Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.47 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.47 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.47 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.47 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.47 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1783245 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL8213846 | 0.80 | NPC1 (0.66) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL1783365 | 0.79 | SMN1; SMN2 (0.57) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL1782973 | 0.79 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL9858666 | 0.76 | ENPP2 (0.71) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL675018 | 0.76 | ENPP2 (0.71) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL9510547 | 0.76 | ENPP2 (0.71) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL22860682 | 0.75 | L3MBTL1 (0.52) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL29597975 | 0.75 | L3MBTL1 (0.52) | SMN1; SMN2RAB9ALMNANPC1HPGD | |
| SCHEMBL28617110 | 0.74 | ALDH1A1 (0.57) | SMN1; SMN2RAB9ALMNANPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8445511-B2 | Quinoline or quinoxaline derivatives for treating neurodegenerative diseases | Centre National de la Recherche Scientifique (SNRS) (FR) | 2013-05-21 | — | — | US | disclosed |
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE(CNRS) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118270-A1 | HETEROCYCLIC DERIVATIVES THAT ARE USED IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | HCRTR2, HCRTR1, CHRNA2 | SMN1; SMN2 166/4885RAB9A 2344/4885LMNA 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.